Kimberly Sippel, MD
Cornea and External Diseases Specialist · New York, NYNPI 1134114549
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $765 of the $882 with a category attached, or 86.6%. 8 manufacturers reported payments, led by Dompe US, Inc. at 42.8% of the total. Reporting peaked in 2019 at $450 and has fallen 96.5% since, to $16 in 2025. That places this record below the midpoint for cornea and external diseases specialist clinicians in NY, where the typical reported total is $2,257.
Across 14 payments — averaging $63.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$377
- Alcon$293
- Mallinckrodt Hospital Products Inc.$100
- Johnson & Johnson Surgical Vision, Inc.$34
- Tarsus Pharmaceuticals, Inc.$28
- Bausch & Lomb Americas Inc.$18
- plus $32 from 2 others
What the payments were for
- Food & beverage$76587%
- Education$11813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 4 | $377 |
| Alcon | 4 | $293 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $34 |
| Tarsus Pharmaceuticals, Inc. | 1 | $28 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$882 in reported general payments places this provider in the 25th percentile of 26 cornea and external diseases specialist providers in New York.
See all cornea and external diseases specialist providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 63 | $47,744 |
| RestasisCyclosporine | 27 | $36,831 |
| XiidraLifitegrast | 12 | $11,881 |
| Bromfenac Sodium | 72 | $10,297 |
| Difluprednate | 93 | $10,055 |
| ProlensaBromfenac Sodium | 25 | $8,575 |
| IlevroNepafenac | 17 | $7,398 |
| Prednisolone Acetate | 173 | $6,368 |
| MoxifloxacinMoxifloxacin Hcl | 260 | $6,291 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 77 | $3,637 |
| Loteprednol Etabonate | 25 | $3,287 |
| Cyclosporine | 11 | $1,944 |
| ValacyclovirValacyclovir Hcl | 28 | $1,282 |
| Acyclovir | 16 | $420 |
| Azelastine Hcl | 16 | $354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $18 | $59,62575 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 26 cornea and external diseases specialist providers in New York.
Other cornea and external diseases specialist in New York
- Christopher StarrNew York$294K
- Jessica CiralskyNew York$6K
- Nadia HaqqieNew York$6K
- Sirikishan ShettyNew York$3K
- Alexandra HerzlichNew York$3K
- Ksenia GomanNew York$2K
- Thomas VoNew York$2K
- Albert RudickNew York$2K
- Matthew NguyenNew York$2K
- Samir JabbourNew York$619
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.